Labcorp Holdings Inc. (LH) company profile
Close on Nov 17, 2026Market cap $29.90BP/E 30.2Yield 0.78%
About Labcorp
Services-Medical Laboratories, SIC 8071
Labcorp Holdings Inc. provides comprehensive laboratory diagnostics and drug development services through two primary segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). Through its Dx segment, the company offers routine clinical testing, specialized esoteric assays, genomic analyses, and direct-to-consumer health panels. Its BLS division delivers central laboratory services, preclinical safety assessments, and analytical solutions that support clinical trials and therapeutic development. Labcorp serves a broad range of clients, including physicians, hospitals, health systems, academic researchers, and individual patients, as well as pharmaceutical, biotechnology, and medical device organizations.
The company operates an extensive service network across North America, Europe, and Asia, which includes more than 2,200 patient service centers and over 7,000 phlebotomists placed directly in customer locations. With nearly 71,000 employees based across 17 countries, Labcorp supports clinical trial activities and serves clients in approximately 100 countries globally. The provided excerpt does not disclose the location of the company's headquarters.
Summary of the business section of Labcorp's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Labcorp Holdings Inc.
- Founded
- 1978
- Headquarters
- Burlington, NC
- Address
- 358 S Main St 27215
- Phone
- (336) 229-1127
- Website
- labcorp.com
- Employees
- 71,000, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Raleigh, North Carolina
Stock & identifiers
- Ticker
- LH
- Exchange
- NYSE
- IPO date
- Mar 29, 1990
- Shares outstanding
- 81M, Oct 29, 2026
- Public float
- $21.70B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, May 13, 2002; 2-for-1, Jun 12, 2001; 1-for-10 reverse, May 4, 2000
- SEC CIK
- 920148
- CUSIP
- 504922105
- ISIN
- US5049221055
- FIGI
- BBG01MMT6PL7
- Share class FIGI
- BBG01MMT6PQ2
- LEI
- OZ7UA8IXAIFILY2VZH07
- EIN
- 99-2588107
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Adam H. Schechter | President & CEO, Director | 102,565 |
| Brian J. Caveney | EVP, Pres of BLS, CMO & CSO | 34,562 |
| Bryan T. Vaughn | EVP and President, Diagnostics | 6,845 |
| Akinbolade Oyegunwa | EVP, CIO & CTO | 5,316 |
| Jonathan C. Meltzer | EVP, COO | 3,620 |
| Amy B. Summy | EVP, Chief Marketing Officer | 6,956 |
| Peter J. Wilkinson | SVP, Chief Accounting Officer | 1,770 |
| Kathryn W. Kyle | EVP, Chief Legal Officer | 3,904 |
| Megan D. Bailey | EVP, Pres, Central Labs & Intl | 5,332 |
| Anita Z. Graham | EVP, CHRO | 5,185 |
| Mark S. Schroeder | EVP, Pres Diagnostics & COO | 15,777 |
| der Vaart Sandra D. van | EVP, Corporate Affairs | 6,239 |
| Julia Aijun Wang | Chief Financial Officer, EVP | 1,817 |
| Glenn A. Eisenberg | Executive Vice President | 41,550 |
| Lance Berberian | EVP, Special Advisor, Strategy | 20,005 |
| Richelle P. Parham | Director | 2,288 |
| Kerrii B. Anderson | Director | 6,851 |
| Kirsten Marie Kliphouse | Director | 3,160 |
| Peter M. Neupert | Director | 13,784 |
| Jeffrey A. Davis | Director | 5,460 |
| Garheng Kong | Director | 13,739 |
| Paul Rothman | Director | 2,571 |
| Kathryn E. Wengel | Director | 4,133 |
| John H. Sampson | Director | – |
| Carulla Victor Bulto | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $18.34M | $30.13M | $4.22M | $150 | $148 |
| FY2024 | $19.33M | $21.33M | $3.72M | $163 | $147 |
| FY2023 | $15.98M | $23.76M | $4.13M | $160 | $143 |
| FY2022 | $14.93M | -$2.32M | $4.39M | $140 | $140 |
| FY2021 | $20.55M | $49.70M | $4.71M | $186 | $143 |
| FY2020 | $14.74M | $18.90M | $3.40M | $120 | $113 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| ADAM H. SCHECHTER President and Chief Executive Officer | $1.44M | – | $11.40M | $2.75M | $2.06M | $687.77K | $18.34M | -5% |
| JULIA A. WANG Executive Vice President and Chief Financial Officer | $737.50K | $200.00K | $2.68M | $649.12K | $706.76K | $40.26K | $5.01M | +49% |
| MEGAN D. BAILEY Executive Vice President and President, Central Laboratories and International | $568.50K | – | $1.26M | $307.91K | $547.62K | $34.75K | $2.72M | – |
| BRIAN J. CAVENEY Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer | $748.46K | – | $2.30M | $557.57K | $719.91K | $25.52K | $4.36M | +22% |
| MARK S. SCHROEDER Former Executive Vice President and President, Diagnostics and Chief Operations Officer | $748.46K | – | $2.51M | $607.51K | $727.40K | $188.83K | $4.79M | +20% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“The Company’s nearly 71,000 employees located across 17 countries are essential to the Company’s ability to innovate and advance science and technology to empower patients, providers, and pharmaceutical companies to make clear and confident decisions.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?